Glenmark Pharmaceuticals has received a significant GST adjudication order from tax authorities, demanding over ₹32.00 crore in alleged dues related to a brand sale transaction. The pharmaceutical company disclosed this development to stock exchanges on April 1, 2026, under regulatory compliance requirements.

GST Demand Details

The Joint Commissioner of Central Goods & Service Tax and Central Excise, Mumbai East Commissionerate, passed the adjudication order under sections 74 and 122 of the Central Goods and Services Tax Act, 2017. The order was issued on March 26, 2026, and received by the company via email on March 31, 2026.

Nature of Alleged Violation

The tax authorities have alleged that Glenmark's transaction involving the sale of a brand in FY 2020-21 should be treated as a "mixed supply" and therefore subject to a higher GST rate. This reclassification forms the basis of the demand for additional tax payment.

The order specifically demands:

• ₹16,05,41,509 on account of CGST/SGST allegedly short-paid by the company
• Applicable interest on the above tax amount
• ₹16,05,41,509 as penalty, equivalent to the alleged short-paid tax amount

Company's Response and Impact Assessment

Glenmark Pharmaceuticals has firmly rejected the tax demand, stating that based on the relevant facts of the case, it does not accept the allegations. The company has announced its intention to file an appeal before the appropriate authority to contest the order.

The company has assessed that there is no material impact on its financials, operations, or other activities due to the adjudication order. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to inform exchanges about regulatory actions and inspections.

Regulatory Compliance

The disclosure follows the mandatory requirements under SEBI listing regulations for transparency regarding regulatory actions. The company has provided detailed information as required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations, ensuring full compliance with disclosure norms for listed entities.

Glenmark Pharmaceuticals has announced a strategic shift to direct commercialization and distribution of RYALTRIS® nasal spray in the United States, effective April 1, 2026. This development marks a significant milestone as RYALTRIS® becomes the company's first innovative product introduced into the US market, representing a meaningful step in building a direct commercial presence in the region.

Strategic Shift to Direct Control

Glenmark Pharmaceuticals Inc., USA will now manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg per spray in the United States. This strategic move allows the company greater operational direction in market engagement and provides closer alignment with healthcare providers while ensuring greater responsiveness to market needs.

Product Profile and Market Positioning

RYALTRIS® was launched in the United States in 2022 and is approved by the US Food and Drug Administration for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and pediatric patients 12 years of age and older. The product represents a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation.

The nasal spray is supplied as a 240-metered spray nasal suspension, targeting the millions of patients across the United States affected by Seasonal Allergic Rhinitis. By combining two established therapies in one formulation, RYALTRIS® offers a convenient treatment option aligned with evolving patient and physician preferences, particularly addressing symptom control and treatment adherence considerations.

Leadership Perspective and Strategic Vision

Marc Kikuchi, President & Business Head, North America, emphasized the significance of this development: "The commercialization by Glenmark for RYALTRIS® in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation."

Kikuchi further highlighted that this announcement marks a significant moment in the company's broader effort to strengthen its innovative businesses in the US and build a more direct, sustainable commercial presence over time. The move enables Glenmark to directly lead brand strategy, market access, and customer engagement for RYALTRIS® in the US market.

Global Market Expansion

RYALTRIS® has established a strong international presence, with approvals in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China. The product's global footprint expanded significantly in FY26, when it was launched in 11 additional markets, bringing its total presence to 55 countries worldwide.

This strategic shift to direct commercialization represents Glenmark's commitment to building a sustainable approach to its US operations while expanding its innovative portfolio in one of the world's largest pharmaceutical markets.